Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

https://www.soho2020.com/

 

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)
C

2020 SOHO Update on IDH Inhibitors in MDS: How Common Are IDH 1/2 Mutations in MDS & What Are They Associated With? Is There Any Activity With Ivosidenib and Enasidenib?

By Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020) FEATURING Courtney D. DiNardo
By Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020) FEATURING Courtney D. DiNardo
9 views
December 11, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray

Featured Video

24:35
Indy Hematology Review

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi
MDS and MPN
09:07
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on MDS: Characteristics and Outcomes of SF3B1 Mutat…

Feat. V. Volpe
14:48
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Update on IDH Inhibitors in MDS: How Common Are IDH 1/2 Mu…

Feat. C. DiNardo
13:30
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on Anemia in MDS: How Does Luspatercept Affect RBC…

Feat. U. Platzbecker
15:33
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on Oral HMAs in MDS: Can FDA-Approved Decitabine/C…

Feat. G. Garcia-Manero
15:52
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on MDS: What Is the Safety and Efficacy of Ven+Aza…

Feat. A. Zeidan
17:02
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on TP53 in MDS: What Is the Correlation of VAF and…

Feat. D. Sallman
18:11
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on MDS: How Do TP53 Mutations Impact Prognosis in …

Feat. D. Sallman
19:05
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on ET: What Does the Diagnostic Algorithm Look Lik…

Feat. A. Tefferi
09:44
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

Next Questions in MF in 2020: What Is MIPSS70-Plus Risk Score? What …

Feat. P. Bose
10:10
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on MDS: What Is the Proposed Treatment Algorithm f…

Feat. G. Garcia-Manero
16:23
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Highlights on Myelofibrosis: What Is the Distinctive Featu…

Feat. R. Rampal
12:50
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Highlights on Myelofibrosis: How Can We Improve Survival A…

Feat. U. Popat
09:59
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on Myelofibrosis: What Are the Long-Term Outcomes …

Feat. J. Joseph
17:07
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

73 y/o Male With Polycythemia Vera With JAK2 V617F Mutation: How Doe…

Feat. L. Michaelis
15:11
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

34 y/o Female With JAK2 V617F Mutated Polycythemia Vera: What PV Tre…

Feat. G. Hobbs
16:58
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

2020 SOHO Updates on Myelofibrosis: What Are the Response Rates With…

Feat. S. Verstovsek